Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell choice for bioartificial livers.

Naoya Kobayashi1, Teru Okitsu, Noriaki Tanaka

  • 1Department of Gastroenterological Surgery, Transplantation, and Surgical Oncology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan. immortal@md.okayama-u.ac.jp

The Keio Journal of Medicine
|October 8, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of Coagulation Phenotypes Using Viscoelastic and Conventional Assays During Veno-Venous Extracorporeal Membrane Oxygenation: A Hierarchical Clustering Analysis.

Artificial organs·2026
Same author

Recurrent laryngeal nerve schwannoma adjacent to the thyroid: a case report.

Journal of medical case reports·2026
Same author

Validation of the Diagnosis Procedure Combination Database in Japan for ICU Research: A Multicenter Comparison with the Japanese Intensive care PAtient Database (JIPAD).

Journal of epidemiology·2026
Same author

Evaluating Clinical Outcomes and Predictive Factors of Treatment Approaches in T1-3N3b Hypopharyngeal Carcinoma: Upfront Neck Dissection Versus Concurrent Chemoradiotherapy.

Head & neck·2025
Same author

Association of Medical Burden and Capacity Changes With Clinical Outcomes Among Patients Without COVID-19 During the Pandemic: A Multicenter Retrospective Cohort Study.

Critical care medicine·2025
Same author

Timing of onset of persistent critical illness in Japan: a nationwide registry study.

The Lancet regional health. Western Pacific·2025

Developing scalable bioartificial liver (BAL) treatments faces challenges with cell sourcing. This study explores a novel method for creating uniform, pathogen-free human liver cell lines for improved BAL therapy.

Area of Science:

  • Hepatology
  • Stem Cell Biology
  • Bioengineering

Background:

  • Current bioartificial liver (BAL) treatments face limitations due to insufficient human hepatocyte availability.
  • Using animal cells for BALs raises concerns regarding pathogen transmission and immune rejection.
  • Alternative cell sources like stem cells are promising but require further development for BAL applications.

Purpose of the Study:

  • To review and discuss optimal cell choices for bioartificial liver (BAL) devices.
  • To present a novel system for generating immortalized human liver cell lines for BALs.
  • To address the need for scalable, safe, and effective cell sources for liver regeneration therapies.

Main Methods:

  • Review of existing literature on cell sources for BALs.

Related Experiment Videos

  • Development of a reversible immortalization system for human liver cells.
  • Utilizing retroviral gene transfer for immortalization and Cre/loxP recombination for site-specific integration.

    • Main Results:

    • Identified limitations of primary human hepatocytes and animal cells for BALs.
    • Demonstrated a method for creating uniform, sterile, and pathogen-free clonal human liver cell lines.
    • Established a system for reversible immortalization, offering controlled cell expansion.

    Conclusions:

    • Scalable and safe cell sources are critical for advancing bioartificial liver (BAL) technology.
    • The presented reversible immortalization system offers a promising strategy for generating clinical-grade cells for BALs.
    • This approach could overcome current limitations and improve the efficacy of liver support therapies.